Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H2A type 1 (H2AC11) is a core histone protein and a component of the nucleosome, the basic unit of chromatin structure in eukaryotic cells[2][3][5]. Two molecules of each core histone (H2A, H2B, H3, and H4) assemble into an octamer, around which DNA coils to form nucleosomes, enabling the efficient packaging and regulation of the genome[2][3][8]. H2AC11 is a replication-dependent canonical histone, meaning it is primarily synthesized and incorporated during DNA replication in S-phase. Its primary functions involve maintaining chromatin structure, controlling DNA accessibility, and contributing to fundamental processes such as transcription regulation, DNA repair, replication, and chromosomal stability[2][3][8]. While not a direct therapeutic target (such as an enzyme or receptor), altered expression of core histones, including H2A family members, has been observed in certain cancers and other disorders linked to chromatin dynamics or genome instability[2][4]. There are no direct drugs or approved biomarkers targeting this canonical histone specifically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H2A type 1 (H2AC11).